Loading...
XNAS
EDIT
Market cap320mUSD
Jul 09, Last price  
3.30USD
1D
-10.08%
1Q
12.24%
Jan 2017
-79.67%
IPO
-82.16%
Name

Editas Medicine Inc

Chart & Performance

D1W1MN
XNAS:EDIT chart
P/E
—
P/S
7.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.65%
Rev. gr., 5y
-14.89%
Revenues
41m
+25.39%
001,629,0006,053,00013,728,00031,937,00020,531,00090,732,00025,544,00019,712,00078,123,00032,314,00040,520,000
Net income
-160m
L-32.49%
-5,349,000-13,685,000-72,900,000-97,183,000-120,324,000-109,954,000-133,746,000-115,976,000-192,502,000-220,432,000-153,219,000-237,093,000-160,060,000
CFO
-165m
L-21.42%
-2,784,000-8,655,000-5,403,000-49,926,000-9,417,000-45,707,000-40,669,000-179,843,000-163,803,000-177,349,000-132,178,000-210,284,000-165,241,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
URL
https://www.editasmedicine.com/
IPO date
Feb 03, 2016
Employees
226
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT